Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.

Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T.

Jpn J Clin Oncol. 2013 Apr;43(4):422-5. doi: 10.1093/jjco/hyt012. Epub 2013 Feb 13.

PMID:
23410901
2.

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.

Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12. Review.

3.

[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].

Katono K, Kasajima M, Ishihara M, Hayashi N, Nagashima Y, Igawa S, Masuda N.

Gan To Kagaku Ryoho. 2013 Mar;40(3):375-7. Japanese.

PMID:
23507602
4.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y, Ma S.

World J Surg Oncol. 2012 Nov 7;10:235. doi: 10.1186/1477-7819-10-235.

5.

Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.

Koma Y, Matsuoka H, Yoshimatsu H, Suzuki Y.

Int J Clin Pharmacol Ther. 2012 Oct;50(10):760-4. doi: 10.5414/CP201759. Review.

PMID:
22853866
6.

Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.

Sekine A, Kato T, Iwasawa T, Baba T, Suido A, Sakuranaka H, Futaki M, Ogura T.

Intern Med. 2016;55(17):2457-61. doi: 10.2169/internalmedicine.55.6102. Epub 2016 Sep 1.

7.

[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].

Fujikura Y, Morishima Y, Ota K, Otsuka S, Homma S, Kurishima K, Hizawa N.

Nihon Kokyuki Gakkai Zasshi. 2010 May;48(5):391-6. Japanese.

PMID:
20560443
8.

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1465-9. doi: 10.1007/s00280-011-1555-6. Epub 2011 Jan 28.

PMID:
21274533
9.

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.

J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.

10.

Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.

Kashima J, Okuma Y, Miwa M, Hosomi Y.

Jpn J Clin Oncol. 2017 Apr 1;47(4):357-362. doi: 10.1093/jjco/hyw206.

PMID:
28064206
11.

Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.

Yang H, Yang X, Zhang Y, Liu X, Deng Q, Zhao M, Xu X, He J.

Target Oncol. 2015 Mar;10(1):135-40. doi: 10.1007/s11523-014-0326-9. Epub 2014 Jul 2.

PMID:
24985049
12.

[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].

Mitsuya K, Nakasu Y, Mizokami Y, Takahashi T, Nakamura Y, Ono A, Toda Y, Yamamoto N, Harada H, Nishimura T.

No Shinkei Geka. 2012 Jun;40(6):503-9. Japanese.

PMID:
22647509
13.

Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.

Wang KF, Chang CY, Chang SC, Liu YC, Yuan MK, Yang YH.

J Chin Med Assoc. 2013 Mar;76(3):173-5. doi: 10.1016/j.jcma.2013.01.012. Epub 2013 Feb 27.

14.

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.

Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, Mitsufuji H, Kubota M, Katagiri M, Masuda N.

Cancer Chemother Pharmacol. 2010 Mar;65(4):803-6. doi: 10.1007/s00280-009-1212-5. Epub 2009 Dec 25.

PMID:
20035424
15.

[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].

Ohashi Y, Suzuki K, Sakurai M, Shino M, Murakami H, Takahashi T, Yamamoto N.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1327-31. Japanese.

PMID:
19692772
16.

Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.

Nagano T, Kotani Y, Kobayashi K, Hatakeyama Y, Hori S, Kasai D, Funada Y, Nishimura H, Kondoh T, Nishimura Y.

Intern Med. 2011;50(24):3019-22. Epub 2011 Dec 15. Review.

17.

Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

Tammaro KA, Baldwin PD, Lundberg AS.

J Oncol Pharm Pract. 2005 Sep;11(3):127-30.

PMID:
16390601
18.

Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.

Hata A, Katakami N, Kunimasa K, Yoshioka H, Fujita S, Kaji R, Tachikawa R, Tomii K, Imai Y, Iwasaku M, Ishida T.

Jpn J Clin Oncol. 2011 Dec;41(12):1366-72. doi: 10.1093/jjco/hyr159. Epub 2011 Nov 3.

PMID:
22058419
19.

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.

Kuiper JL, Smit EF.

Lung Cancer. 2013 Apr;80(1):102-5. doi: 10.1016/j.lungcan.2012.12.024. Epub 2013 Feb 1.

PMID:
23375403
20.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938

Supplemental Content

Support Center